Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors

Biochemical and Biophysical Research Communications

Volumn 361, Issue 2, 2007, Pages 549-554

  Rumpold, Holger ^a   Salvador, Christina ^a   Wolf, Anna Maria ^a   Tilg, Herbert ^a   Gastl, Guenther ^a   Wolf, Dominik ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cancer; Drug resistance; Drug transporter; MDR 1; PgP; Proteasome inhibitors

Indexed keywords

BORTEZOMIB; GLYCOPROTEIN P; MLN 273; MULTIDRUG RESISTANCE PROTEIN 1; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPOSON;

APOPTOSIS; BORONIC ACIDS; CELL PROLIFERATION; DIPEPTIDES; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; LEUKEMIA; P-GLYCOPROTEIN; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 34547505458     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.07.049     Document Type: Article

References (28)

1. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., and Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348 (2003) 2609-2617
2. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben Yehuda D., Lonial S., Goldschmidt H., Reece D., San Miguel J.F., Blade J., Boccadoro M., Cavenagh J., Dalton W.S., Boral A.L., Esseltine D.L., Porter J.B., Schenkein D., and Anderson K.C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352 (2005) 2487-2498
3. Kartner N., Riordan J.R., and Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221 (1983) 1285-1288
4. Michieli M., Damiani D., Ermacora A., Masolini P., Raspadori D., Visani G., Scheper R.J., and Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br. J. Haematol. 104 (1999) 328-335
5. Raspadori D., Damiani D., Michieli M., Stocchi R., Gentili S., Gozzetti A., Masolini P., Michelutti P., Geromin A., Fanin R., and Lauria F. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Haematologica 87 (2002) 1135-1140
6. Schaich M., Soucek S., Thiede C., Ehninger G., and Illmer T. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br. J. Haematol. 128 (2005) 324-332
7. Walter R.B., Gooley T.A., van der Velden V.H., Loken M.R., van Dongen J.J., Flowers D.A., Bernstein I.D., and Appelbaum F.R. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 109 (2007) 4168-4170
8. Sonneveld P., Durie B.G., Lokhorst H.M., Marie J.P., Solbu G., Suciu S., Zittoun R., Lowenberg B., and Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The leukaemia Group of the EORTC and the HOVON. Lancet 340 (1992) 255-259
9. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., Dorr R., Karanes C., Hynes H.E., Doroshow J.H., Shurafa M., and Appelbaum F.R. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 (2001) 3212-3220
10. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
11. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5 (2006) 219-234
12. Stuart D.D., Kao G.Y., and Allen T.M. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther. 7 (2000) 466-475
13. Kobayashi H., Dorai T., Holland J.F., and Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 54 (1994) 1271-1275
14. Nieth C., Priebsch A., Stege A., and Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545 (2003) 144-150
15. Wu H., Hait W.N., and Yang J.M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 63 (2003) 1515-1519
16. Rumpold H., Wolf A.M., Gruenewald K., Gastl G., Gunsilius E., and Wolf D. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp. Hematol. 33 (2005) 767-775
17. Fisher R.I., Bernstein S.H., Kahl B.S., Djulbegovic B., Robertson M.J., de Vos S., Epner E., Krishnan A., Leonard J.P., Lonial S., Stadtmauer E.A., O'Connor O.A., Shi H., Boral A.L., and Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 24 (2006) 4867-4874
18. Goy A., Younes A., McLaughlin P., Pro B., Romaguera J.E., Hagemeister F., Fayad L., Dang N.H., Samaniego F., Wang M., Broglio K., Samuels B., Gilles F., Sarris A.H., Hart S., Trehu E., Schenkein D., Cabanillas F., and Rodriguez A.M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 23 (2005) 667-675
19. Strauss S.J., Maharaj L., Hoare S., Johnson P.W., Radford J.A., Vinnecombe S., Millard L., Rohatiner A., Boral A., Trehu E., Schenkein D., Balkwill F., Joel S.P., and Lister T.A. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J. Clin. Oncol. 24 (2006) 2105-2112
20. Blaney S.M., Bernstein M., Neville K., Ginsberg J., Kitchen B., Horton T., Berg S.L., Krailo M., and Adamson P.C. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J. Clin. Oncol. 22 (2004) 4804-4809
21. Papandreou C.N., Daliani D.D., Nix D., Yang H., Madden T., Wang X., Pien C.S., Millikan R.E., Tu S.M., Pagliaro L., Kim J., Adams J., Elliott P., Esseltine D., Petrusich A., Dieringer P., Perez C., and Logothetis C.J. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 22 (2006) 2108-2121
22. Ryan D.P., Appleman L.J., Lynch T., Supko J.G., Fidias P., Clark J.W., Fishman M., Zhu A.X., Enzinger P.C., Kashala O., Cusack Jr. J., and Eder J.P. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 107 (2006) 2482-2489
23. Shah M.H., Young D., Kindler H.L., Webb I., Kleiber B., Wright J., and Grever M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 10 (2004) 6111-6118
24. Chauhan D., Hideshima T., Mitsiades C., Richardson P., and Anderson K.C. Proteasome inhibitor therapy in multiple myeloma. Mol. Cancer Ther. 4 (2005) 686-692
25. Chauhan D., Hideshima T., and Anderson K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer 95 (2006) 961-965
26. Dalton W.S., Grogan T.M., Meltzer P.S., Scheper R.J., Durie B.G., Taylor C.W., Miller T.P., and Salmon S.E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7 (1989) 415-424
27. Minderman H., Zhou Y., O'Loughlin K.L., and Baer M.R. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother. Pharmacol. 60 (2007) 245-255
28. Shringarpure R., Catley L., Bhole D., Burger R., Podar K., Tai Y.T., Kessler B., Galardy P., Ploegh H., Tassone P., Hideshima T., Mitsiades C., Munshi N.C., Chauhan D., and Anderson K.C. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br. J. Haematol. 134 (2006) 145-156